1Glass PS,Gan TJ,Howell S.A review of the pharmacokinetics and pharmacodynamics of remifentanil.Anesth Analg,1999,89:s7-14.
2Kazmaier S,Hanekop GG,Buhre W,et al.Myocardial consequences of remifentanil in patients with coronary artery disease.Br J Anaesth,2000,84:578-583.
3Elliott P,O'Hare R,Bill KM,et al.Severe cardiovascular depression with remifentanil.Anesth Analg,2000,91:58-61.
4Sebel PS,Hoke TF,Westmoreland C,et al.Histamine concentrations and hemodynamic response after remifentanil.Anesth Analg,1995,80:990-993.
5Myre K,Raeder J,Rostrup M,et al.Catecholamine release during laparoscopic fundoplication with high and low doses of remifentanil.Acta Anaesthesiol Scand,2003,47:267-273.
6Unlugenc H,Itegin M,Ocal I,et al.Remifentanil produces vasorelaxation in isolated rat thoracic aorta strip.Acta Anaesthesiol Scand,2003,47:65-69.
7Casati A,Fanelli G,Albertin A,et al.Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation:a double-blind comparison.Eur J Anaesthesiol,2001,18:108-112.
8Sneyd JR,Camu F,Doenicke A,et al.Remifentanil and fentanylduring anesthesia for major abdominal and gynaecological surgery.An open,comparative study of safety and efficacy.Eur J Anaesth,2001,18:605-614.
2[1]Gepts E. Pharmacokinetics concepts for TCI anaesthesia[J]. Anaesthesia. 1998, 53: S4-12
3[2]Glen JB. Development of 'Diprifusor': a TCI system for propofol[J]. Anaesthesia, 1998, 53: S13-21
4[3]Glass PSA, Gan TJ, Howell S. A review of the pharmacokinetics and pharmacodynamics of remifentanil[J]. Anesth Analg, 1999, 89: S7-14
5[4]Vuyk J, Mertens MJ, Olofsen E, et al. Propofol anesthesia and rational opioid selection[J]. Anesthesiology, 1997, 87: 1549-1562
6[5]Hoymork SC, Reder J, Grimsmo B, et al. Bispectral index, predicted and measured drug levels of target-controlled infusions of remifentanil and propofol during laparoscopic cholecystectomy and emergence[J]. Acta Anaesth Scand, 2000, 44: 1138-1144
7[6]Glass PSA, Shafer SL, Reves JG. Intravenous drug delivery system. In: Miller RD. Anesthesia[M].5th ed.USA: Churchill livingstone, 2001. 377-411
8[7]Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil[J]. Anesthesiology, 1997,86:10-23
9[8]Drover DR, Lemmens HJM. Population pharmacodynamics and pharmacokinetics of remifentanil as a supplement to nitrous oxide anesthesia for elective abdominal surgery[J]. Anesthesiology, 1998,89:869-877
10[9]Lang E, Kaplia A, Shlugman D, et al. Reduction of isoflurane minimal alveolar concentration by remifentanil[J]. Anesthesiology, 1996,85:721-728
6Chart KC, Godman MJ. Morphological variations of fossa ovalis atrial septal depects secundum: feasibility for transcutaneous closure with the clam-shell deveice. Br Heart J, 1993,69:52-55.
7Hellenbrand WE , Fahey JT, McGowan F,et al. Transesophageal echocardiography guidanceof the tmscatheter closure of atrial septal defects. Am J Cardiol, 1990,66:207-213.
8Zabal C, Lince R, Buendia A, et al, Interventional cardiology in Congenital heart disease,Arch Inst Cardiol Mex, 1999,69:63-68.
9Fischer G, Stieh J, Uebing A, et al. experience with transeatheter closure of sccundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patient. Heart,2003,89:1999-204.
10Rice MJ, McDonald R W, Li X, et al. New technology and methologies for intraoperative, perioperative, and intraprocedural monitoring of surgical and catheter interventions for congenital heart disease. Echocardiography, 2002, 19:725-734.
